Details for Patent: 10,610,125
✉ Email this page to a colleague
Which drugs does patent 10,610,125 protect, and when does it expire?
Patent 10,610,125 protects IDHIFA and TIBSOVO and is included in two NDAs.
This patent has fourteen patent family members in eight countries.
Summary for Patent: 10,610,125
Title: | Methods and compositions for cell-proliferation-related disorders |
Abstract: | Methods of treating and evaluating subjects having neoactive mutants are described herein. |
Inventor(s): | Dang; Lenny (Boston, MA), Fantin; Valeria (Burlingame, CA), Gross; Stefan (Brookline, MA), Jang; Hyun Gyung (Waltham, MA), Jin; Shengfang (Newton, MA), Salituro; Francesco G. (Marlborough, MA), Saunders; Jeffrey O. (Lincoln, MA), Su; Shin-San Michael (Boston, MA), Yen; Katharine (Wellesley, MA) |
Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 15/589,615 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,610,125 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,610,125
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION | ⤷ Sign Up | ||||
Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION | ⤷ Sign Up | ||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG) | ⤷ Sign Up | ||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG) | ⤷ Sign Up | ||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG) | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,610,125
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010223919 | ⤷ Sign Up | |||
Australia | 2016204346 | ⤷ Sign Up | |||
Canada | 2755394 | ⤷ Sign Up | |||
China | 102985557 | ⤷ Sign Up | |||
China | 108524505 | ⤷ Sign Up | |||
European Patent Office | 2406389 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |